tirzepatide trial results for Heart Failure with Preserved Ejection Fraction and Obesity Tirzepatide once weekly for the

Unmatched Healing and Regeneration Properties Heres where GHK-CU truly stands out

These findings suggest GLP-1 medications may influence the brains reward system, but larger and longer studies are still needed

Cardiovascular protection is an important consideration

This dose was chosen to be conservative in assessing the drugs impact on behaviour, but it is possible that a higher dose could reveal more consistent effects across different dosing regimens

Pharma leaders must think beyond obesity: communicating the broader long-term health benefits of GLP-1s, as part of a comprehensive treatment plan and across a spectrum of outcomes, will be key to building trust and driving adherence What do you think

P.CuiF.et al (2020)